Scarica l'app Stockscreener
10.73
4.79%
-0.54
Precedente Chiudi:
$11.27
Aprire:
$11.98
Volume 24 ore:
154.98K
Relative Volume:
1.90
Capitalizzazione di mercato:
$148.66M
Reddito:
-
Utile/perdita netta:
$-8.89M
Rapporto P/E:
-15.33
EPS:
-0.7
Flusso di cassa netto:
$-6.48M
1 W Prestazione:
+20.02%
1M Prestazione:
+28.89%
6M Prestazione:
+13.31%
1 anno Prestazione:
-18.77%
Intervallo 1D:
$10.51
$11.98
Intervallo di 1 settimana:
$9.20
$11.98
Portata 52W:
$7.78
$14.47
Greenwich Lifesciences Inc Stock (GLSI) Company Profile
Nome
Greenwich Lifesciences Inc
Settore
Industria
Telefono
203-434-3290
Indirizzo
3992 BLUEBONNET DR, BUILDING 14, STAFFORD
Confronta GLSI con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GLSI
Greenwich Lifesciences Inc
|
10.73 | 156.14M | 0 | -8.89M | -6.48M | -0.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Greenwich Lifesciences Inc Stock (GLSI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-20 | Iniziato | Noble Capital Markets | Outperform |
| 2021-09-01 | Iniziato | H.C. Wainwright | Buy |
Greenwich Lifesciences Inc Borsa (GLSI) Ultime notizie
Aug Retail: Will Greenwich LifeSciences Inc stock outperform growth indexesTreasury Yields & Expert-Curated Trade Recommendations - moha.gov.vn
Noble Financial Issues Pessimistic Outlook for GLSI Earnings - MarketBeat
(GLSI) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com
Greenwich LifeSciences completes enrollment in Phase III trial arm - Investing.com
Greenwich LifeSciences completes enrollment in Phase III trial arm By Investing.com - Investing.com India
Greenwich LifeSciences Announces Completion of Enrollment in the Open Label Arm of FLAMINGO-01 - The Manila Times
How Greenwich LifeSciences Inc. stock reacts to global recession fearsMarket Growth Summary & Real-Time Volume Trigger Notifications - Newser
What analysts say about Greenwich LifeSciences Inc stockShort Selling Opportunities & Identify Winning Stocks - earlytimes.in
Greenwich LifeSciences reaches 1,000 patient screening milestone By Investing.com - Investing.com Nigeria
Greenwich Lifesciences provides global update on Flamingo-01 - marketscreener.com
Greenwich LifeSciences reaches 1,000 patient screening milestone - Investing.com
Greenwich LifeSciences, Inc. Reports Milestone Achievement in FLAMINGO-01 Clinical Trial with Over 1,000 Patients Screened - Quiver Quantitative
Greenwich LifeSciences Provides Global Update on FLAMINGO-01, Screening Over 1,000 Patients to Date - Yahoo Finance
Greenwich LifeSciences (GLSI) Stock Analysis Report | Financials & Insights - Benzinga
Greenwich LifeSciences, Inc. (GLSI) stock price, news, quote and history - Yahoo Finance UK
Insider Buying: Greenwich LifeSciences (NASDAQ:GLSI) CEO Purchases $38,502.00 in Stock - MarketBeat
(GLSI) Risk Channels and Responsive Allocation - news.stocktradersdaily.com
Greenwich LifeSciences CEO Patel buys $38k in GLSI stock By Investing.com - Investing.com Canada
Is Greenwich LifeSciences Inc. stock safe for conservative investorsRate Cut & Real-Time Volume Analysis - newser.com
Why Greenwich LifeSciences Inc. stock remains on watchlistsEarnings Risk Summary & Risk Controlled Swing Trade Alerts - newser.com
Greenwich LifeSciences Inc. stock daily chart insightsQuarterly Growth Report & Technical Pattern Recognition Alerts - newser.com
What recovery options are there for Greenwich LifeSciences Inc.July 2025 Summary & Expert Approved Momentum Trade Ideas - newser.com
(GLSI) Movement as an Input in Quant Signal Sets - news.stocktradersdaily.com
Can Greenwich LifeSciences Inc. stock surprise with earnings upside2025 EndofYear Setup & Expert Verified Movement Alerts - newser.com
Greenwich LifeSciences (NASDAQ:GLSI) Releases Earnings Results, Meets Expectations - MarketBeat
How to interpret RSI for Greenwich LifeSciences Inc. stockMarket Growth Summary & Expert Curated Trade Ideas - newser.com
Key resistance and support levels for Greenwich LifeSciences Inc.Watch List & Community Verified Swing Trade Signals - newser.com
Published on: 2025-11-14 19:58:18 - newser.com
Published on: 2025-11-14 17:28:35 - newser.com
Greenwich LifeSciences, Inc. SEC 10-Q Report - TradingView
Published on: 2025-11-14 13:13:03 - newser.com
When is the best time to exit Greenwich LifeSciences Inc.Trade Exit Summary & AI Based Buy and Sell Signals - newser.com
What candlestick patterns are forming on Greenwich LifeSciences Inc.July 2025 Setups & Verified Swing Trading Watchlists - newser.com
Several Insiders Invested In Greenwich LifeSciences Flagging Positive News - Yahoo Finance
Is Greenwich LifeSciences Inc a good long term investmentLong-Term Growth Stocks & Small Budget Capital Growth - earlytimes.in
Published on: 2025-11-13 03:10:11 - newser.com
Greenwich LifeSciences (NASDAQ:GLSI) CEO Buys $89,358.00 in Stock - MarketBeat
Greenwich LifeSciences CEO Makes Bold Stock Purchase! - TipRanks
Greenwich LifeSciences CEO and CFO Snehal Patel Acquires 10,600 Shares - TradingView
[Form 4] Greenwich LifeSciences, Inc. Insider Trading Activity - Stock Titan
Greenwich Lifesciences Inc Azioni (GLSI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Greenwich Lifesciences Inc Azioni (GLSI) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Patel Snehal | CEO and CFO |
Nov 07 '25 |
Buy |
8.43 |
10,600 |
89,358 |
5,583,502 |
| Patel Snehal | CEO and CFO |
Oct 31 '25 |
Buy |
9.26 |
2,300 |
21,298 |
5,572,902 |
| Patel Snehal | CEO and CFO |
Apr 25 '25 |
Buy |
9.88 |
3,600 |
35,568 |
5,570,602 |
| Patel Snehal | CEO and CFO |
Apr 17 '25 |
Buy |
8.98 |
5,400 |
48,492 |
5,567,002 |
| Patel Snehal | CEO and CFO |
Apr 07 '25 |
Buy |
9.10 |
3,600 |
32,760 |
5,561,602 |
| Patel Snehal | CEO and CFO |
Apr 04 '25 |
Buy |
8.73 |
5,500 |
48,015 |
5,558,002 |
| Patel Snehal | CEO and CFO |
Jan 10 '25 |
Buy |
12.51 |
2,500 |
31,275 |
5,552,502 |
| Patel Snehal | CEO and CFO |
Jan 07 '25 |
Buy |
13.75 |
1,800 |
24,750 |
5,550,002 |
| Patel Snehal | CEO and CFO |
Jan 06 '25 |
Buy |
13.31 |
1,100 |
14,641 |
5,548,202 |
| Patel Snehal | CEO and CFO |
Jan 03 '25 |
Buy |
12.95 |
3,400 |
44,030 |
5,547,102 |
1.08%
0.91%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):